openPR Logo
Press release

Burkitt Lymphoma Market Expected to Witness Significant Growth by 2032 | DelveInsight

04-04-2025 02:26 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: ABNewswire

Burkitt Lymphoma Market Expected to Witness Significant Growth

The Key Burkitt lymphoma companies in the market include - Jazz Pharmaceuticals, Xencor, ADC Therapeutics, Cothera Bio, Merck, and Cornerstone Pharmaceuticals, among others.

The Burkitt lymphoma market is expected to experience significant growth across the seven major markets (7MM), which include the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. This growth is driven by several factors, including the increasing prevalence of the disease, advancements in diagnostic capabilities, and a strong pipeline of new therapies. Key Burkitt lymphoma companies, such as Jazz Pharmaceuticals, Xencor, ADC Therapeutics, Cothera Bio, Merck, and Cornerstone Pharmaceuticals, among others , are leading innovation and addressing unmet treatment needs.

DelveInsight's latest comprehensive research report, "Burkitt Lymphoma Market Insight, Epidemiology And Market Forecast - 2032 [https://www.delveinsight.com/report-store/burkitt-lymphoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]," presents critical insights into the evolving Burkitt lymphoma market landscape across 7MM. The report highlights significant growth in the Burkitt lymphoma treatment market during the forecast period of 2019-2032, driven by increased awareness, improved diagnostic capabilities, and the emergence of novel therapeutics.

Download the report to understand which factors are driving the Burkitt lymphoma therapeutic market @ Burkitt lymphoma Market Trends [https://www.delveinsight.com/sample-request/burkitt-lymphoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]

Burkitt lymphoma is an aggressive form of non-Hodgkin B-cell lymphoma that begins in B-cells. The disease is frequently associated with Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), and chromosomal translocations causing overexpression of the oncogene c-myc. While the exact cause remains unknown, geographical factors influence risk patterns, with malaria exposure being significant in endemic regions like Africa and HIV representing the primary risk factor elsewhere. The World Health Organization classifies Burkitt lymphoma into three distinct types: Endemic (primarily affecting African children), Sporadic (occurring globally), and Immunodeficiency-associated (most common in people with HIV).

According to epidemiological data cited in the report, Burkitt lymphoma represents approximately half of all malignant non-Hodgkin lymphomas in children and around 2% in adults across Europe and North America, with males being disproportionately affected compared to females. Further research indicates that in children under 18 years old, the incidence is approximately 3-6 cases per 100K children annually. For sporadic Burkitt lymphoma, the estimated annual incidence is 4 per 1 million children under 16 years of age and around 2.5 per 1 million in adults. The immunodeficiency-associated variant has a notably higher incidence of 22 per 100K in the United States.

Discover evolving trends in Burkitt lymphoma patient pool forecasts @ Burkitt lymphoma Epidemiology Analysis [https://www.delveinsight.com/sample-request/burkitt-lymphoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]

The DelveInsight report also discusses the current and future treatment strategies for Burkitt lymphoma. The existing treatment market for Burkitt lymphoma primarily focuses on intravenous chemotherapy regimens, utilizing agents such as cyclophosphamide, cytarabine, doxorubicin, etoposide, methotrexate, and vincristine. RITUXAN (GeneNtech/Biogen) remains the only approved drug used in combination with various chemotherapy protocols, including R-CODOX-M, R-IVAC, and DA-EPOCH-R. In some cases, surgical intervention may be necessary to address intestinal complications. The overall cure rate for sporadic Burkitt lymphoma approaches an impressive 90% in pediatric and young adult populations.

The Burkitt lymphoma drugs development market shows promising activity with several emerging therapies in the pipeline. Notable among these is ADCT-402 (ADC Therapeutics), an antibody-drug conjugate targeting CD19 on B-cells. PC-002 (Cothera Biosciences) is another investigational agent that works by inhibiting survivin expression in tumor cells. Other notable candidates are CPX-351 (Jazz Pharmaceuticals) and Plamotamab (Xencor). Key companies advancing the Burkitt lymphoma therapeutics market include ADC Therapeutics, Cothera Bio, Merck, and Cornerstone Pharmaceuticals, among others.

A robust pipeline of several therapies, including gene-modified cell therapies and small molecules, is under development. In October 2024, the FDA granted Fast Track designation to Cothera Bioscience's clinical program PC-002 for the treatment of relapsed or refractory Burkitt Lymphoma. The clinical outcomes and prognostic implications of rituximab in pediatric B-cell non-Hodgkin lymphoma, including Burkitt lymphoma, which represented 53.2% of cases in the study, show positive results as of March 2025. These recent developments underscore the progress toward improving outcomes for Burkitt lymphoma.

Unlock which emerging Burkitt lymphoma drug is expected to capture the largest market share in 7MM by 2034. Visit the Burkitt lymphoma Market Insights [https://www.delveinsight.com/sample-request/burkitt-lymphoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]

According to DelveInsight's analysis, the Burkitt lymphoma market faces several challenges, including delayed diagnosis and limited approved therapeutic options. However, the Burkitt lymphoma market shows substantial growth, driven by increased disease awareness, enhanced healthcare spending, and the introduction of novel targeted therapies with improved efficacy profiles. The robust pipeline of innovative treatments and growing research focus on addressing unmet needs position the Burkitt lymphoma treatment market for significant expansion across the 7MM.

Table of Contents

1.

Report Introduction

2.

Executive Summary of Burkitt Lymphoma

3.

SWOT Analysis of Burkitt Lymphoma

4.

Burkitt Lymphoma: Patient Share (%) Overview at a Glance

5.

Burkitt Lymphoma: Market Overview (%) at a Glance

6.

Disease Background and Overview

7.

Epidemiology and Patient Population

8.

Country-Specific Patient Population of Burkitt Lymphoma

9.

Current Treatment and Medical Practices

10.

Patient Journey

11.

Unmet Needs

12.

Key Endpoint of Clinical Trials

13.

Emerging Therapies

14.

Conjoint Analysis of Burkitt Lymphoma Therapies

15.

Burkitt Lymphoma: Market Size of 7MM

16.

Country-Wise Market Analysis (2019-2032)

17.

Market Access and Reimbursement of Burkitt Lymphoma

18.

Market drivers

19.

Market barriers

20.

Appendix

21.

DelveInsight Capabilities

22.

Disclaimer

23.

About DelveInsight

Related Reports

B-cell Lymphoma Pipeline Insight [https://www.delveinsight.com/report-store/b-cell-lymphomas-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]

B-cell Lymphoma Pipeline Insight provides comprehensive insights about the B-cell Lymphoma pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the B-cell Lymphoma companies, including Lisocabtagene maraleucel, Hoffmann-La Roche (ROG), Nektar Therapeutics (NKTR), Miltenyi Biomedicine GmbH, AVM Biotechnology, Lin BioScience, Inc, Incyte Corporation (INCY), ADC Therapeutics S.A., Genor Biopharma, Beijing InnoCare Pharma Tech, CARGO Therapeutics (CRGX), Chia Tai Tianqing Pharmaceutical Group, SystImmune, LIBO PHARMA, Abclon, BeiGene, Cellectis, Iovance Biotherapeutics (IOVA), Guangzhou Excelmab, Y-mAbs Therapeutics (YMAB), TG Therapeutics, Sutro Biopharma, AbbVie (ABBV), Aleta Biotherapeutics, Janssen Research & Development, Lantern Pharma, Beijing Immunochina Medical Science and Technology, Bantam Pharmaceutical, Lin Bioscience, SFA Therapeutics, neoX Biotech, March Biosciences, and HUTCHMED (HCM) among others.

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.

Media Contact
Company Name: DelveInsight
Contact Person: Arpit Anand
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=burkitt-lymphoma-market-expected-to-witness-significant-growth-by-2032-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Burkitt Lymphoma Market Expected to Witness Significant Growth by 2032 | DelveInsight here

News-ID: 3956265 • Views:

More Releases from ABNewswire

Apollo Group TV Announces Major Expansion Into Global Live Sports And Channels Including Availability on Mobile, Tablet and Smart TV Worldwide
Apollo Group TV Announces Major Expansion Into Global Live Sports And Channels I …
Apollo Group TV [https://myapollogroup.tv/], the plus streaming service that connects you with your favorite films, series, and live channels, is very happy to inform you about the big step into global live sports and channels which indeed is a big upgrade of the present-day reality. So from now on Apollo Group TV will be available on more devices, phones, tablets, and smart TVs all over the world, and thus the
Firm Fencing | Perth Fence Installers Awarded 2025 Quality Business Award for Best Fencing Contractor - Shire of Mundaring, WA
Firm Fencing | Perth Fence Installers Awarded 2025 Quality Business Award for Be …
Image: https://www.abnewswire.com/upload/2025/10/0ec84268c866d1038906121e599ab5c8.jpg Perth, WA - Firm Fencing | Perth Fence Installers [https://www.perthfenceinstallers.com.au/] is proud to announce it has been awarded the 2025 Quality Business Award for Best Fencing Contractor in the Shire of Mundaring, Western Australia. This prestigious recognition affirms the firm's commitment to exceptional workmanship, customer-first service, and enduring quality in the fencing industry. Based in Perth and servicing the greater metropolitan and regional areas including the Shire of Mundaring, Firm
Marina Bay City Lombok Becomes the World's First City to Ban Interest on Home Loans
Marina Bay City Lombok Becomes the World's First City to Ban Interest on Home Lo …
Lombok, Indonesia - October 31, 2025 - In a groundbreaking move redefining modern finance and community development, Marina Bay City in South Lombok, Indonesia, has officially announced a ban on all home lending that charges interest. This makes it one of the first cities in the world to completely reject interest-based finance systems within its borders. The multi-billion-dollar development, already under construction, is envisioned as a "Freedom and Wellness City" designed
Portland Office Movers Report 40% Surge in Commercial Relocations as Remote Work Policies Shift
Portland Office Movers Report 40% Surge in Commercial Relocations as Remote Work …
Portland's commercial moving sector reports 40% growth as businesses restructure office space for hybrid work. Redefyne Moving & Storage documents trends showing companies downsizing, relocating, and adapting workspaces across the metro area. The commercial moving industry in Portland is experiencing a significant transformation as businesses throughout the metro area reassess office space requirements. Recent data reveals a 40% increase in commercial relocations during the past 18 months, signaling a significant shift

All 5 Releases


More Releases for Burkitt

Burkitt Lymphoma Treatment Market Advances Through Targeted Drug Development | N …
Burkitt Lymphoma Treatment Market Overview Burkitt Lymphoma Treatment Market is projected to grow from USD 1.2 billion in 2025 to USD 2.0 billion by 2032, registering a CAGR of 7.5% during the forecast period. The latest report (2025-2032) on the Burkitt Lymphoma Treatment Market by Coherent Market Insights offers an in-depth analysis of market trends, growth factors, challenges, and competition. It explores market size, revenue, production, consumption, and CAGR, using reliable research
Comprehensive Market Forecast for Burkitt Lymphoma Therapeutics: Market Analysis …
Burkitt Lymphoma Therapeutics Market Snapshot: Insight into Market Trends and Movements Burkitt lymphoma therapeutics focus on the treatment of this aggressive hematological cancer, utilizing chemotherapy, targeted therapies, and immunotherapy. The Burkitt Lymphoma Therapeutics market is experiencing significant growth, driven by increasing incidences of this rare but aggressive lymphoma, particularly in pediatric populations. Advancements in treatment protocols, including combination therapies and more effective monoclonal antibodies, are enhancing patient outcomes. Increased awareness and early
Burkitt Lymphoma Market 2023: Epidemiology, Industry Trends, Opportunity and For …
IMARC Group has recently released a report titled "Burkitt Lymphoma Market: Analysis of Epidemiology, Industry Trends, Size, Share, and Future Forecast (2023-2033)" that presents a comprehensive assessment of the burkitt lymphoma market size, latest trends, and growth forecast. The report provides an extensive overview of the latest market trends, growth prospects, investment opportunities, and industry outlook, as well as an in-depth analysis of the disease landscape, market scenario, and growth
Burkitt Lymphoma Treatment Market Poised to Expand at a Robust Pace Over 2027
Burkitt Lymphoma Treatment Market research report is the new statistical data source added by CMI. According to this report, Burkitt Lymphoma Treatment Market research is an intelligence report with meticulous efforts undertaken to study the right and valuable information. The data which has been looked upon is done considering both, the existing top players and the upcoming competitors. Business strategies of the key players and the new entering market industries are
Global Burkitt Lymphoma Therapeutics Market Size, Status and Forecast 2019-2025
Market Research Report Store offers a latest published report on Burkitt Lymphoma Therapeutics Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. This report focuses on the key global Burkitt Lymphoma Therapeutics players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.To analyze the Burkitt Lymphoma Therapeutics with
Burkitt Lymphoma Treatment Market Revenue Opportunies By Key Vendors Burkitt lym …
Burkitt lymphoma is a cancer of the lymphatic system, which develops from abnormal B lymphocytes and is characterized by rapid growth. Burkitt lymphoma usually causes lymph node enlargement in various parts of the body, including spleen, liver, bone marrow, and central nervous system. Burkitt lymphoma is a type of high-grade non-Hodgkin lymphoma (NHL). The World Health Organization has classified Burkitt lymphoma as an endemic that affects children in Africa aged